Evaluation of Serum Proinflammatory Cytokine IL‐17A and Tight Junction Protein Claudin‐1 in Psoriasis
Contrast Media & Molecular Imaging · 2022-01 · 2022 (1)
DOI: 10.1155/2022/6092808 ↗Abstract
Objective . This study aimed to estimate serum IL‐17A and Claudin‐1 levels, investigate their correlation, and evaluate their diagnostic significance as potential blood‐based biomarkers in psoriasis. Methods . Serum IL‐17A and Claudin‐1 concentrations were determined using enzyme‐linked immunosorbent assay (ELISA). Statistical analyses were performed to determine differences in serum levels of IL‐17A and Claudin‐1, their bivariable correlation with psoriasis severity, as Psoriasis Area Severity Index (PASI), and their predictive abilities using receiver operating characteristic (ROC) curves. Results . Significantly higher IL‐17A and lower Claudin‐1 levels were found in psoriasis ( p < 0.05). PASI did not correlate significantly with either IL‐17A or Claudin‐1 in psoriasis and their subtypes. The only significant correlation between serum IL‐17A and Claudin‐1 was shown in late‐onset psoriasis ( r = 0 . 630 , p = 0 . 028 ). ROC curve analysis indicated the serum IL‐17A, serum Claudin‐1, and combination of IL‐17A and serum Claudin‐1 for predicting psoriasis with the areas under the curve (AUC) of 0.951 ( p < 0.0001), 0.709 ( p = 0.0119), and 0.949 ( p < 0.0001), respectively. Moreover, the potential role in distinguishing between early‐onset and late‐onset psoriasis: we obtained serum IL‐17A, serum Claudin‐1, and their combination AUC of 0.590 ( p = 0.3126), 0.741 ( p = 0.0045), and 0.741 ( p = 0.0067), respectively. However, none of the serum IL‐17A, serum Claudin‐1, and their combination was well‐performed discriminating mild psoriasis from moderate‐to‐severe psoriasis with AUC of 0.553 ( p = 0.5596), 0.518 ( p = 0.8539), and 0.559 ( p = 0.5225), respectively. Conclusion . These preliminary results suggest that the serum Claudin‐1 as a potential biomarker and the relationship and possible regulatory interactions between IL‐17A and Claudin‐1 in psoriasis are distinguishable by age of onset.
EUVIMED